4th Quarter - Report

CSL BEHRING LLC for CSL BEHRING LLC

Firm
Client
Income
—
Expenses
$320,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. HR 133--Consolidated Appropriations Act of 2021--Sec. 104. Extension of medicare patient IVIG access demonstration project. Sec. 117. Continued coverage of certain temporary transitional home infusion therapy services. CMS-5528, Interim Final Rule; Most Favored Nation (MFN) Model--Paramaters for definition of qualified drugs for inclusion in the final rule establishing a Most Favored Nation reimbursement model under Medicare Part B Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.

LobbyistCovered position, as disclosed
PATRICK COLLINS —
JULIA GRANT —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 133 (116th), S. 3587 (116th), H.R. 6218 (116th), H.R. 7839 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.